Abstracts tagged "immunology"

Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 1013 • ACR Convergence 2021
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Kate Webb¹, Thandeka Moyo-Gwete², Simon Mendelsohn³, Claire Butters⁴, Simone Richardson⁵, Heidi Facey-Thomas⁴, Debbie Abrahams⁴, Mashudu Madzivhandila⁵, Zanele Makhado⁵, Frances Ayres⁵, William Horsnell⁶, Neilia Manamela⁵, Richard Baguma³, Stanley Kimbung Mbandi³, Mzwandile Erasmus³, Thomas Scriba³, Liesl Zühlke⁷, Penny Moore⁵, George Kassiotis⁸ and Christiaan Scott⁴, ¹Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, ²National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, ³South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, ⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ⁵National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa, ⁷Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁸Retroviral Immunology, Francis Crick Institute, London, United Kingdom
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
Abstract Number: 0262 • ACR Convergence 2021
High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
Clément TRIAILLE¹, Cécile BOULANGER², Tatiana SOKOLOVA¹, Laurent MERIC de BELLEFON³, Adrien NZEUSSEU TOUKAP⁴, Christine GALANT⁵, Nisha LIMAYE⁶, Bernard LAUWERYS⁷ and Patrick DUREZ⁸, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Service d’Hématologie, Oncologie et Rhumatologie pédiatrique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, ⁵Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium
Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…
Abstract Number: 1092 • ACR Convergence 2021
Altered Metabolic Pathways in Synovial Fibroblasts of Individuals at Risk of Developing Rheumatoid Arthritis
Tineke de Jong¹, Simone Denis¹, Paul Tak², Riekelt Houtkooper¹ and Lisa van Baarsen¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Candel Therapeutics, Cambridge, United Kingdom
Background/Purpose: Cellular metabolism has been studied in fibroblast-like synoviocytes (FLS) of rheumatoid arthritis (RA) and osteoarthritis (OA) patients and raises the question whether observed metabolic…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
Abstract Number: 1224 • ACR Convergence 2021
Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab
Samuel Bitoun¹, Bineta Ly², Signe Hässler³, Audrey Paoletti⁴, Aude Gleizes⁵, Salima Hacein-Bey⁵, Philippe Bröet³, Marc Pallardy⁶ and Xavier Mariette⁷, ¹Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, ²INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, ³CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, ⁴INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, ⁵Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, ⁶Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, ⁷Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
Abstract Number: 0439 • ACR Convergence 2021
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Amy Cunningham-Bussel¹, Jiaqi Wang², Lauren Prisco³, Lily Martin², Kathleen Vanni², Alessandra Zaccardelli², Mazen Nasrallah⁴, Lydia Gedmintas², Lindsey MacFarlane⁵, Nancy Shadick⁶, Mark M. Awad⁷, Osama E. Rahma⁷, Nicole LeBoeuf⁸, Ellen Gravallese⁹ and Jeffrey Sparks², ¹Brigham and Women's, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Pound Ridge, MA, ⁴MGH, Somerville, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Dana-Farber Cancer Institute, Boston, ⁸Brigham and Women's Hospital, Department of Dermatology, Boston, MA, ⁹Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
Abstract Number: 1250 • ACR Convergence 2021
Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue
Clément TRIAILLE¹, Tatiana SOKOLOVA¹, Gaëlle TILMAN¹, Laurent MERIC de BELLEFON², Christine GALANT³, Patrick DUREZ⁴, Bernard LAUWERYS⁵ and Nisha LIMAYE⁶, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Our goal was to assess histological and transcriptomic effects of Abatacept (ABA) on RA synovium, and to compare them with previously published data obtained…
Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Meagan Chriswell¹, Jennifer Seifert², Michelle Bloom³, Cliff Rims⁴, Marie Feser⁵, Kevin Deane⁶, Jill Norris⁷, Eddie James⁸, Jane Buckner⁹, William Robinson¹⁰, V. Michael Holers¹¹ and Kristine Kuhn¹², ¹UC Denver SOM, Denver, CO, ²University of Colorado School of Medicine, Littleton, CO, ³Stanford University, Redwood City, CA, ⁴Benaroya Research Institute, Seattle, WA, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado Denver, Denver, CO, ⁷Colorado School of Public Health, Aurora, CO, ⁸Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Stanford University, Palo Alto, CA, ¹¹University of Colorado, Denver, CO, ¹²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Blake Warner¹, Billel Gasmi², David Kleiner³, Paola Perez Riveros⁴, Daniel Barber⁵, Shunsuke Sakai⁵ and Alan Baer⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, ²National Cancer Institute, Bethesda, MD, ³National Cancer Institute, Bethesda, ⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Nick Huang¹, Akshay Patel¹, Zachary Oaks¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
Abstract Number: 1996 • ACR Convergence 2020
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Kevin Winthrop¹, Juan Vargas², Edit Drescher³, Conrado Garcia⁴, Alan Friedman⁵, Jeffrey Enejosa⁵, Nasser Khan⁵, Yihan Li⁵, Justin Klaff⁵ and Alan Kivitz⁶, ¹Oregon Health & Science University, Portland, OR, ²Quantum Research, Puerto Varas, Chile, ³Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁴Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, ⁵AbbVie Inc., North Chicago, IL, ⁶Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA
Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…
Abstract Number: 0450 • ACR Convergence 2020
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Anne Sofie Sørensen¹, Morten Nørgaard Andersen¹, Kristian Juul-Madsen², Cæcilie Deisting Skejø¹, Henrik Schmidt¹, Thomas Vorup-Jensen¹ and Tue Wenzel Kragstrup¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark
Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].